Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis

This issue chosen by the Editor of Intestinal Research is “Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis” performed by Ajit Sood, et al. Although available evidence is limited and previous studies have demonstrated variable results, these results suggest that fecal microbiota transplantation (FMT) has the potential as an effective and safe treatment option for UC when standard treatments have failed. This study showed 4-weekly multi-session FMT via colonoscopy could be effective in patients with steroid dependent UC. Steroid free clinical remission (46.3%), clinical response (75.6%) and endoscopic remission (63.4%) were achieved at 24 week, those are better compared with previous studies. In addition to this article, read other articles about FMT in UC Best regards,

Figure & Data

References

Citations

Citations to this article as recorded by

Related articles

Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
Ajit Sood, Ramit Mahajan, Garima Juyal, Vandana Midha, Charanpreet Singh Grewal, Varun Mehta, Arshdeep Singh, Mohan C Joshi, Vikram Narang, Kirandeep Kaur, Hasrat Sidhu. Intest Res. 2019;17(1):76-86
https://doi.org/10.5217/ir.2018.00089
Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of steroid-dependent ulcerative colitis
Young-Seok Cho. Intest Res. 2019;17(1):6-8
https://doi.org/10.5217/ir.2018.00171
Current new challenges in the management of ulcerative colitis
Tomohiro Fukuda, Makoto Naganuma, Takanori Kanai. Intest Res. 2019;17(1):36-44
https://doi.org/10.5217/ir.2018.00126
Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial
Samuel P. Costello, Patrick A. Hughes, Oliver Waters, Robert V. Bryant, Andrew D. Vincent, Paul Blatchford, Rosa Katsikeros, Jesica Makanyanga, Melissa A. Campaniello, Chris Mavrangelos, Carly P. Rosewarne, Chelsea Bickley, Cian Peters, Mark N. Schoeman, Michael A. Conlon, Ian C. Roberts-Thomson, Jane M. Andrews. JAMA. 2019;321(2):156-164
https://doi.org/10.1001/jama.2018.20046
Fecal transplantation for treatment of inflammatory bowel disease
Aamer Imdad, Maribeth R Nicholson, Emily E Tanner‐Smith, Joseph P Zackular, Oscar G Gomez‐Duarte, Dawn B Beaulieu, Sari Acra. Cochrane Database Syst Rev. 2018;13(11):CD012774
https://doi.org/10.1002/14651858.CD012774.pub2
Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?
Natalie Grace Fairhurst, Simon P. L. Travis. Intest Res . 2018;16(2):209-215
https://doi.org/10.5217/ir.2018.16.2.209
Fecal microbiota transplantation for recurrent Clostridium difficileinfection in a patient with ulcerative colitis
Kosaku Nanki, Shinta Mizuno, Katsuyoshi Matsuoka, Keiko Ono, Shinya Sugimoto, Hiroki Kiyohara, Mari Arai, Moeko Nakashima, Kozue Takeshita, Keiichiro Saigusa, Mitsutoshi Senoh, Tadashi Fukuda, Makoto Naganuma, Haru Kato, Wataru Suda, Masahira Hattori, Takanori Kanai. Intest Res . 2018;16(1):142-146
https://doi.org/10.5217/ir.2018.16.1.142
Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun. Intest Res . 2017;15(2):145-146
https://doi.org/10.5217/ir.2017.15.2.145
Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients
Shinta Mizuno, Kosaku Nanki, Katsuyoshi Matsuoka, Keiichiro Saigusa, Keiko Ono, Mari Arai, Shinya Sugimoto, Hiroki Kiyohara, Moeko Nakashima, Kozue Takeshita, Makoto Naganuma, Wataru Suda, Masahira Hattori, Takanori Kanai. Intest Res. 2017;15(1):68-74
https://doi.org/10.5217/ir.2017.15.1.68